Newsroom

Industry News

7 Feb

Actinium Pharmaceuticals Announces Pipeline Expansion with Initiation of Clinical Trial of Actimab-M in Multiple Myeloma

NEW YORK, Feb. 07, 2017 (GLOBE NEWSWIRE) — Actinium Pharmaceuticals, Inc.  (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that a Phase 1 clinical trial studying Actimab-M in multiple myeloma has been initiated. Actimab-M is comprised...

Read more

7 Feb

MicroCap Review Magazine Winter/Spring 2017 Issue Now Available

LOS ANGELES, Feb. 7, 2017 /PRNewswire/ — SNN Incorporated, a global multimedia financial news and publishing company focused on the MicroCap stock market, and publisher of the MicroCap Review Magazine, is pleased to announce the release of the MicroCap Review Magazine Winter/Spring 2017 issue online and in print. The Winter/Spring...

Read more

7 Feb

Cellectar Biosciences to Present at 2017 BIO CEO & Investor Conference

MADISON, Wis., Feb. 07, 2017 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim Caruso, will present at the 2017 BIO CEO & Investor Conference in on Monday, February 13th at 2:00 PM ET in the Windsor...

Read more

3 Feb

Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) — Intellipharmaceutics International Inc. (IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for...

Read more

3 Feb

Asterias Biotherapeutics Extends the Expiration Date of Certain Warrants and Provides Update on Cash Position

FREMONT, Calif., Feb. 3, 2017 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine, today announced the company is extending the expiration date of certain warrants. The decision to extend the warrants takes into consideration Asterias’ recent announcement of positive interim efficacy...

Read more

3 Feb

Catalyst Biosciences to Present at 19th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 03, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 19th Annual BIO CEO...

Read more

2 Feb

MTBC to Present at the 2nd Annual Disruptive Growth & Healthcare Conference

NEW YORK, NY / ACCESSWIRE / February 2, 2017 / MTBC (MTBC) (MTBCP), a leading provider of proprietary, cloud-based electronic health records, practice management, and mHealth solutions announced today that it will be presenting in New York City at the 2nd annual Disruptive Growth & Healthcare Conference on Wednesday,...

Read more

2 Feb

CymaBay Announces Pricing of Public Offering of Common Stock

NEWARK, Calif., Feb. 02, 2017 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet need, today announced the pricing of its previously announced underwritten public offering of 5,181,348 shares of its common stock at a...

Read more

Page 5 of 216« First...34567...102030...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address